The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer

Oncologist

Volumn 6, Issue SUPPL. 1, 2001, Pages 4-7

  Gridelli, Cesare ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Best supportive care; ELVIS; Vinorelbine

Indexed keywords

NAVELBINE;

ADVANCED CANCER; AGED; ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035130402     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_1-4     Document Type: Conference Paper

References (14)

1. Lung cancer in the elderly
2. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly
3. What do we know about the variables influencing clinical decision-making in elderly cancer patients?
4. Cisplatin nephrotoxicity in elderly patients with lung cancer
5. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer
6. Multi-institutional phase II study of vinorelbine (Navelbine) in non-small cell lung cancer
7. Non-small cell lung cancer: A study of long-term survival after vinorelbine monotherapy
8. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients
9. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomised trial
10. Survival advantage for patients with stage IV NSCLC treated with single agent Navelbine in a randomized controlled trial
11. Weekly vinorelbine in elderly patients with non-small cell lung cancer
12. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients
13. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study
14. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer